ESTRO 2024 - Abstract Book

S2866

Interdisciplinary - Health economics & health services research

ESTRO 2024

Conclusion:

The global public and philanthropic cancer research funding allocated to radiotherapy is disproportionately low. It appears unevenly distributed both geographically and relative to the global burden of disease. There is a need to match industry-facilitated advances in radiotherapy technology with biological optimisation, which should be supported by targeted allocation of public and philanthropic research funding. Additionally, investment is heavily weighted to the pre-clinical/translational phase with health services and global health research receiving extremely limited resources, despite their scope to significantly improve care and outcomes by optimising the delivery of existing treatments. Global cancer research funders should consider their approach to radiotherapy research funding, recognising the burden of disease and relative scope for improved outcomes through revised investment strategies.

Keywords: Research funding, Global investment, Grant

References:

1. Dodkins J, Hopman WM, Wells JC, et al. Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials. Int J Radiat Oncol Biol Phys 2022;113(3):500-08. doi: 10.1016/j.ijrobp.2022.01.053 [published Online First: 20220211.

2.

Aggarwal A, Lewison G, Rodin D, et al. Radiation Therapy Research: A Global Analysis 2001-2015. Int J

Radiat Oncol Biol Phys 2018;101(4):767-78. doi: 10.1016/j.ijrobp.2018.03.009

3.

https://www.healthdata.org/research-analysis/gbd. Accessed 25/10/23.

3228

Digital Poster

Analysing healthcare benefits and resource implications of lung cancer CT screening in Jordan

Ahmed Salem 1,2,3 , Mohannad Al-Qatanany 1 , Delara Dahabreh 1 , Fanar Al-Samarat 1 , Bilal Al-Badayneh 1

1 The Hashemite University, Faculty of Medicine, Zarqa, Jordan. 2 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 3 Christie NHS Foundation Trust, Clinical Oncology Dept., Manchetser, United Kingdom

Purpose/Objective:

Lung cancer, driven by high smoking prevalence, is a leading cause of cancer deaths in Jordan. Low-dose computed tomography (LDCT) lung screening programs are effective to reduce lung cancer mortality.(1,2) We evaluated Jordan's capacity for implementation of lung cancer screening, considering the availability of CT scanners and